Tolerability of crisantaspase [L-asparaginase Erwinia chrysanthemi; Erwinaze] in patients with acute lymphoblastic leukaemia who developed hypersensitivity to Escherichia coli-derived asparaginase: compassionate use protocol

Trial Profile

Tolerability of crisantaspase [L-asparaginase Erwinia chrysanthemi; Erwinaze] in patients with acute lymphoblastic leukaemia who developed hypersensitivity to Escherichia coli-derived asparaginase: compassionate use protocol

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2012

At a glance

  • Drugs Crisantaspase (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 20 Dec 2012 New trial record
    • 10 Dec 2012 Data were presented at the American Society of Hematology Annual Meeting and Exposition, according to a Jazz Pharmaceuticals plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top